Last reviewed · How we verify
Comparator: rizatriptan benzoate
Rizatriptan benzoate is a selective serotonin 5-HT1B/1D receptor agonist that constricts cranial blood vessels and inhibits neuropeptide release to relieve migraine headaches.
Rizatriptan benzoate is a selective serotonin 5-HT1B/1D receptor agonist that constricts cranial blood vessels and inhibits neuropeptide release to relieve migraine headaches. Used for Acute migraine with or without aura.
At a glance
| Generic name | Comparator: rizatriptan benzoate |
|---|---|
| Also known as | MK0462 |
| Sponsor | Organon and Co |
| Drug class | Triptan (5-HT1B/1D receptor agonist) |
| Target | 5-HT1B receptor, 5-HT1D receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Rizatriptan works by binding to 5-HT1B and 5-HT1D receptors on cranial blood vessels and trigeminal nerve terminals. This causes vasoconstriction of dilated intracranial vessels and reduces the release of vasoactive neuropeptides involved in migraine pathophysiology, thereby terminating acute migraine attacks.
Approved indications
- Acute migraine with or without aura
Common side effects
- Dizziness
- Somnolence
- Asthenia/fatigue
- Nausea
- Chest pain/pressure
- Palpitations
Key clinical trials
- Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072) (PHASE3)
- Study to Test an Approved Product in the Early Treatment of Migraine (0462-066) (PHASE3)
- Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071) (PHASE3)
- Study to Test an Approved Product in the Early Treatment of Migraine (0462-065) (PHASE3)
- A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis (PHASE3)
- Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081) (PHASE3)
- Treatment of Multiple Attacks of Acute Migraine (0462-025) (PHASE3)
- Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: rizatriptan benzoate CI brief — competitive landscape report
- Comparator: rizatriptan benzoate updates RSS · CI watch RSS
- Organon and Co portfolio CI